New York / Anatolia
** Aziz Singer, Nobel Laureate:
The molecule “EdU”, which is widely used in laboratory experiments, can be used in the treatment of brain cancer
The molecule has been one of the most widely used chemicals in molecular biology since 2008
This chemical is characterized by its ability to cross the so-called blood-brain barrier and move to brain tissue
The Turkish Nobel Prize-winning scientist based in the United States, Professor Aziz Singer, revealed the possibility of using a molecule called “EdU”, which is widely used in laboratory experiments, in the treatment of brain cancer.
In an interview with Anadolu Agency, Singer, 75, indicated that he had published a scientific article regarding his new discovery in the Journal of the US National Academy of Sciences, one of the most respected scientific journals in the United States in the past few days.
Singer stated that the molecule “EdU” has been considered one of the most prominent chemicals used in molecular biology since 2008.
And he added, “I spent 10 years decoding the DNA repair mechanism that enabled me to win the Nobel Prize. Then, last January, we started working on a new study in which we observed some activities related to killing cancer cells.”
He noted that he went to Turkey to attend a medical program in the same month, where he continued to work with the 10-member team in the United States upon his return.
He added, “We ran two experiments related to the activities of killing cancer cells (..) We were not completely sure of the results, so we continued to work after my return from Turkey to the United States.”
He continued, “We conducted all the necessary tests, and confirmed the ability of this molecule to kill cancer cells.”
Singer stated, “Over the past years, scientists have sought to take advantage of the EdU molecule, as it was implanted in cells, but the results showed that it killed both normal and cancerous cells.”
He added, “Therefore, studies on this topic did not continue, and scientists were not able at the time to find out the reason that drives this molecule to kill both normal and cancerous cells.”
Regarding the properties of the molecule (EdU), he said: “This chemical is characterized by its ability to cross the so-called blood-brain barrier and move to brain tissue.”
He added, “We combined the activity of the drug called (cisplatin), which is used in the treatment of 80 percent of cancer patients, with the mentioned molecule, and we were able to kill cancer cells and enter the brain cells.”
** Preliminary experiments on mice
The Turkish scientist reported that the molecule (EdU), which is the short name for “5-ethynyl-2-deoxyuridine”, “is a synthetic form of thymine found in natural DNA.”
He added, “At this stage, we are working to test the capabilities of the new treatment in mice first, and after obtaining positive results, we will test the treatment on volunteer patients.”
He continued, “We have agreed with a professor of brain cancer sciences to conduct experiments on mice, and together we will start working in this field and conduct the necessary tests in November or December.”
“If we can kill the brain tumor in mice, we will move to humans,” he added.
Noting that mice experiments may take two years, Singer pointed out, “These studies are usually long and expensive, and often do not yield results, and that the success rate of this discovery in human treatment at this stage is 3 percent,” calling on “cancer patients to optimism for good.
He stressed the need to work and persevere in order to achieve results in the interest of serving humanity, saying: “We were born into this world and we will leave it sooner or later (..) We have to leave something useful before leaving.”
He called on young people to stay away from the use of social media, saying: “I have used social media for a while, and I saw that it does more harm than good, so I stopped using it (..) We have to work and persevere in order to leave something good in this world before it is We leave him.”
The news published on the official page of Anadolu Agency is an abbreviation for a part of the news that is presented to subscribers via the News Stream System (HAS). To subscribe to the agency, please contact the following link.